ProBioGen and LAVA Therapeutics N.V. sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific
Berlin, Germany and Utrecht, Netherlands, June 22, 2021:
ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA's pipeline.
Under the agreement and using its CHO.RiGHT® expression platform, including its DirectedLuck™ Transposase technology for the generation of stable high-titer cell lines, ProBioGen will conduct cell line development of a novel gamma-delta bsTCE.
"We are delighted to continue our collaboration with LAVA to develop cell lines for another novel gamma-delta bsTCE. Our proven cell line development platform, which also includes our Transposase technology, is perfectly suited for novel protein formats", said ProBioGen's Chief Executive Officer Dr. Lutz Hilbrich.
"Based on the great results from our previous agreement, we would look forward working with ProBioGen again", commented Stephen Hurly, Chief Executive Officer and President of LAVA Therapeutics. "ProBioGen exceeded our expectations and proved to be a scientifically driven partner with a proven development platform and a dedicated analytical panel for bispecific antibody formats."
ProBioGen is a specialist in the development and manufacturing of complex therapeutic proteins.
The combination of ProBioGen's CHO.RiGHT® expression platform and state-of-the-art process development platforms, together with intelligent and innovative product-specific technologies yield biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and robust GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 25 years. At two locations in Berlin, more than 200 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.
LAVA Therapeutics N.V. is a biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary platform. The company's approach leverages bispecific antibodies to activate Vγ9Vδ2 T cells upon binding to membrane-expressed tumor associated antigens. Activated Vγ9Vδ2 T cells are engaged for direct tumor cell killing. The company's lead program, LAVA-051, is expected to enter a Phase 1/2a clinical study in hematologic malignancies in the first half of 2021.
The company has established a highly experienced research and development team located in Utrecht, the Netherlands and Philadelphia, USA.
ProBioGen Press Contact:
LAVA Therapeutics N.V. Contact: